Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 6/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616920 | 1.00 | C5AR1 (0.43) | C5AR1KCNK3KCNK9JAK1ACHE | |
| SCHEMBL26752557 | 0.90 | JAK1 (0.39) | C5AR1KCNK3KCNK9JAK1ACHE | |
| SCHEMBL29428691 | 0.90 | JAK1 (0.39) | C5AR1KCNK3KCNK9JAK1ACHE | |
| SCHEMBL25324710 | 0.88 | C5AR1 (0.44) | C5AR1BRS3CFTRALDH1A1GAA | |
| SCHEMBL23409272 | 0.87 | TMEM97 (0.42) | JAK1GPR119 | |
| SCHEMBL25322135 | 0.87 | TMEM97 (0.42) | JAK1GPR119 | |
| SCHEMBL29003001 | 0.85 | AGTR2 (0.41) | JAK1GPR119HDAC1 | |
| SCHEMBL30124161 | 0.85 | AGTR2 (0.41) | JAK1GPR119HDAC1 | |
| SCHEMBL19616741 | 0.85 | C5AR1 (0.47) | C5AR1ACHEBRS3CFTR | |
| SCHEMBL30793072 | 0.85 | JAK1 (0.40) | KCNK3KCNK9JAK1GPR119KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20240034733-A1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-02-01 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4240489-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4216951-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022098625-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022066646-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034733-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | C5AR1 3993/4885KCNK3 4586/4885KCNK9 4514/4885 |
| US-20230357277-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | C5AR1 3993/4885KCNK3 4586/4885KCNK9 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.